Taligen Therapeutics, Inc.: Series B $65M

Posted in I - Series B, Q - 1Q08, R - ROCKY MOUNTAIN, X - AMD, X - Asthma, X - Inflammation

Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.

Genizon Biosciences, Inc.: Series D $31M

Posted in I - Series D, Q - 1Q08, R - INTERNATIONAL, X - Asthma, X - Biomarker, X - Crohn's, X - Schizophrenia

Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.

MAP Pharmaceuticals, Inc.: Series D $50M

Posted in I - Series D, Q - 2Q07, R - WEST, X - Asthma

MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.

SunTen Phytotech Co., Ltd.: Series B $10M

Posted in I - Series B, R - INTERNATIONAL, X - Asthma

SunTen Phytotech (Taipei, Taiwan) a botanical drug development company, has raised $10M in Series B funding led by PacLink Capital, Taiwan Global Biofund Venture and 3V SourceOne Venture Capital.

to top of page...